Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index
暂无分享,去创建一个
L S Freedman | L. Freedman | D. Henson | L. Ries | D E Henson | L Ries | M Carriaga | M. Carriaga | Donald Earl Henson | Laurence S. Freedman | Marisa Carriaga
[1] H. Bloom,et al. Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.
[2] J. Vegelius,et al. Analysis of reproducibility of subjective grading systems for breast carcinoma. , 1979, Journal of clinical pathology.
[3] G. Bonadonna,et al. Tumor grade as a prognostic factor in primary breast cancer. , 1989, European journal of cancer & clinical oncology.
[4] H. Bloom,et al. Impact of tumor grade and host resistance on survival of women with breast cancer , 1971, Cancer.
[5] R. Gelber,et al. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis , 1986, Cancer.
[6] W. A. Evans. Histological Factors in the Prognosis of Mammary Cancer Treated by Radical Operation and X-Rays , 1933 .
[7] R. Scarff. Prognosis in carcinoma of the breast. , 1938, British Journal of Radiology.
[8] L. Freedman,et al. Histological grade and other prognostic factors in relation to survival of patients with breast cancer. , 1979, British Journal of Cancer.
[9] G. Garas,et al. Intralaboratory variations in the grading of breast carcinoma. , 1982, Archives of pathology & laboratory medicine.
[10] B. V. Pedersen,et al. Histologic malignancy grading of invasive ductal breast carcinoma. A regression analysis of prognostic factors in low‐risk carcinomas from a multicenter trial , 1987, Cancer.
[11] Yasargil Ec. HOMOGRAFT REPLACEMENT OF THE AORTIC VALVE. , 1964, Lancet.
[12] S. Wyard,et al. THE NATURAL DURATION OF CANCER , 1925, Canadian Medical Association journal.
[13] C. Elston,et al. THE ASSESSMENT OF HISTOLOGICAL DIFFERENTIATION IN BREAST CANCER , 1984 .
[14] C. Redmond,et al. Histologic grading of breast cancer. , 1980, Pathology annual.
[15] Donald E. Henson,et al. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .
[16] H. Bloom. Prognosis in Carcinoma of the Breast , 1950, British Journal of Cancer.
[17] C. Redmond,et al. Pathologic findings from the national surgical adjuvant breast and bowel projects (NSABP) prognostic discriminants for 8‐year survival for node‐negative invasive breast cancer patients , 1990, Cancer.
[18] R W Blamey,et al. Prognostic factors in breast cancer -- the formation of a prognostic index. , 1979, Clinical oncology.
[19] J. Glick. Meeting highlights: adjuvant therapy for breast cancer. , 1988, Journal of the National Cancer Institute.
[20] C. Redmond,et al. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Henson De. End points and significance of reproducibility in pathology. , 1989 .
[22] S Friedman,et al. Prognostic value of histologic grade nuclear components of Scarff‐Bloom‐Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas , 1989, Cancer.
[23] Henson De. Grading of tumors. , 1988 .
[24] R. Blamey,et al. A prognostic index in primary breast cancer. , 1982, British Journal of Cancer.
[25] R. W. Scarff,et al. THE POSITION OF HISTOLOGY IN THE PROGNOSIS OF CARCINOMA OF THE BREAST. , 1928 .
[26] Henson De. The histological grading of neoplasms. , 1988 .
[27] G M Clark,et al. How to use prognostic factors in axillary node-negative breast cancer patients. , 1990, Journal of the National Cancer Institute.
[28] W. McGuire. Estrogen receptor versus nuclear grade as prognostic factors in axillary node negative breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.